Literature DB >> 21695649

Cyclic nucleotides and phosphodiesterases in monocytic differentiation.

Angie L Hertz1, Joseph A Beavo.   

Abstract

Monocytes are immune cells that can differentiate into a number of cell types including macrophages, dendritic cells, and osteoclasts upon exposure to various cytokines. The phenotypes of these differentiated cells are highly heterogeneous and their differentiation can be affected by the cyclic nucleotides, 3'-5'-cyclic adenosine monophosphate (cAMP) and 3'-5'-cyclic guanosine monophosphate (cGMP). The intracellular levels of cAMP and cGMP are controlled through regulation of production by adenylyl and guanylyl cyclases and through degradation by cyclic nucleotide phosphodiesterases (PDEs). PDE inhibition and subsequent changes in cyclic nucleotide levels can alter the final phenotype of a differentiating monocyte with regards to surface marker expression, gene expression, or changes in secreted chemokine and cytokine levels. The differentiation process itself can also be either inhibited or augmented by changes in cyclic nucleotide levels, depending on the system being studied and the timing of cyclic nucleotide elevation. This chapter explores the effects of PDE inhibition and increases in cGMP and cAMP on monocytic differentiation into osteoclasts, dendritic cells, and macrophages.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21695649      PMCID: PMC4038123          DOI: 10.1007/978-3-642-17969-3_16

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  98 in total

1.  The cyclic AMP-Epac1-Rap1 pathway is dissociated from regulation of effector functions in monocytes but acquires immunoregulatory function in mature macrophages.

Authors:  Tone Bryn; Milada Mahic; Jorrit M Enserink; Frank Schwede; Einar Martin Aandahl; Kjetil Taskén
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

Review 2.  A single second messenger: several possible cellular responses depending on distinct subcellular pools.

Authors:  Karin E Bornfeldt
Journal:  Circ Res       Date:  2006-10-13       Impact factor: 17.367

3.  Phosphodiesterase 4 inhibitor regulates the TRANCE/OPG ratio via COX-2 expression in a manner similar to PTH in osteoblasts.

Authors:  Hyojung Park; Soo Young Lee; Dong-Seok Lee; Mijung Yim
Journal:  Biochem Biophys Res Commun       Date:  2007-01-02       Impact factor: 3.575

4.  Cyclic nucleotide analogs as probes of signaling pathways.

Authors:  Heiko Poppe; Sergei D Rybalkin; Holger Rehmann; Thomas R Hinds; Xiao-Bo Tang; Anne E Christensen; Frank Schwede; Hans-Gottfried Genieser; Johannes L Bos; Stein O Doskeland; Joseph A Beavo; Elke Butt
Journal:  Nat Methods       Date:  2008-04       Impact factor: 28.547

5.  Phosphodiesterase 4 inhibitor rolipram potentiates the inhibitory effect of calcitonin on osteoclastogenesis.

Authors:  Ken-ichi Miyamoto; Tatsuo Nishioka; Yoshihiro Waki; Masaaki Nomura; Hiromu Katsuta; Koichi Yokogawa; Hitoshi Amano
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

Review 6.  Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use.

Authors:  Andrew T Bender; Joseph A Beavo
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 7.  Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases.

Authors:  Rodolphe Fischmeister; Liliana R V Castro; Aniella Abi-Gerges; Francesca Rochais; Jonas Jurevicius; Jérôme Leroy; Grégoire Vandecasteele
Journal:  Circ Res       Date:  2006-10-13       Impact factor: 17.367

Review 8.  The osteoclast: a multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell.

Authors:  Zvi Bar-Shavit
Journal:  J Cell Biochem       Date:  2007-12-01       Impact factor: 4.429

9.  Rolipram, a phosphodiesterase 4 inhibitor, suppresses PGE2-induced osteoclast formation by lowering osteoclast progenitor cell viability.

Authors:  Hyojung Park; Mijung Yim
Journal:  Arch Pharm Res       Date:  2007-04       Impact factor: 4.946

10.  Different mitogen-activated protein kinase-dependent cytokine responses in cells of the monocyte lineage.

Authors:  Susan J Tudhope; Tricia K Finney-Hayward; Andrew G Nicholson; Ruth J Mayer; Mary S Barnette; Peter J Barnes; Louise E Donnelly
Journal:  J Pharmacol Exp Ther       Date:  2007-10-05       Impact factor: 4.030

View more
  8 in total

1.  Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors.

Authors:  Ester Sciaraffia; Antonella Riccomi; Ragnar Lindstedt; Valentina Gesa; Elisa Cirelli; Mario Patrizio; Maria Teresa De Magistris; Silvia Vendetti
Journal:  J Leukoc Biol       Date:  2014-03-20       Impact factor: 4.962

2.  Gene-expression signatures differ between different clinical forms of familial hemophagocytic lymphohistiocytosis.

Authors:  Janos Sumegi; Shawnagay V Nestheide; Michael G Barnes; Joyce Villanueva; Kejian Zhang; Alexei A Grom; Alexandra H Filipovich
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

3.  A dominant variant in the PDE1C gene is associated with nonsyndromic hearing loss.

Authors:  Li Wang; Yong Feng; Denise Yan; Litao Qin; M'hamed Grati; Rahul Mittal; Tao Li; Abhiraami Kannan Sundhari; Yalan Liu; Prem Chapagain; Susan H Blanton; Shixiu Liao; Xuezhong Liu
Journal:  Hum Genet       Date:  2018-06-02       Impact factor: 4.132

4.  Interaction between saliva's adenosine and tick parasitism: effects on feeding and reproduction.

Authors:  Elen Anatriello; Carlo José Freire Oliveira; Nathália Baptista Oliveira; Andressa Fisch; Cristiane Maria Milanezi; João Santana da Silva; Isabel Kinney Ferreira de Miranda-Santos; Beatriz Rossetti Ferreira
Journal:  Parasit Vectors       Date:  2017-07-10       Impact factor: 3.876

5.  A three-gene signature based on tumour microenvironment predicts overall survival of osteosarcoma in adolescents and young adults.

Authors:  Chunkai Wen; Hongxue Wang; Han Wang; Hao Mo; Wuning Zhong; Jing Tang; Yongkui Lu; Wenxian Zhou; Aihua Tan; Yan Liu; Weimin Xie
Journal:  Aging (Albany NY)       Date:  2020-12-03       Impact factor: 5.682

Review 6.  PDE inhibition in distinct cell types to reclaim the balance of synaptic plasticity.

Authors:  Ben Rombaut; Sofie Kessels; Melissa Schepers; Assia Tiane; Dean Paes; Yevgeniya Solomina; Elisabeth Piccart; Daniel van den Hove; Bert Brône; Jos Prickaerts; Tim Vanmierlo
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

Review 7.  Molecular mechanisms underlying β-adrenergic receptor-mediated cross-talk between sympathetic neurons and immune cells.

Authors:  Dianne Lorton; Denise L Bellinger
Journal:  Int J Mol Sci       Date:  2015-03-11       Impact factor: 5.923

Review 8.  The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT.

Authors:  John D Clements; Elizabeth B Norton
Journal:  mSphere       Date:  2018-07-25       Impact factor: 4.389

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.